How to Fix Injectable COGS in QuickBooks (Step-by-Step for Med Spa Owners)

Most med spas expense Allergan and Galderma invoices to a generic supplies account in QuickBooks. That hides your real injectable margin. Here is the 6-step fix.

Allergan's wholesale acquisition cost for Botox is approximately $6.56 per unit as of February 2024, per Allergan corporate disclosures. A standard 20-unit treatment costs roughly $131 in product.

A 60-unit treatment costs roughly $394. If your QuickBooks P&L is not capturing that cost against injectable revenue, your gross margin figure is wrong, and every business decision you make from it is built on a bad number.

This is a fixable accounting problem, not a pricing or volume problem. The fix is a chart of accounts restructure, a few product item setups in QuickBooks Online, and a monthly reconciliation habit. Med spas that correct this setup typically find their actual injectable margin running 45-65%, compared to the 80%+ that miscoded books show by default.

Six steps fix it. There is also a before-and-after calculation using a $20,000/month injectable revenue example so you can see what your P&L should actually show.

Why QuickBooks shows the wrong injectable margin by default

Most med spa QuickBooks files have a single expense account for medical or office supplies. When an Allergan, Galderma, Merz, Evolus, or Revance invoice arrives, it gets coded there. The cost hits the P&L immediately. Injectable service revenue gets recorded when the treatment is billed.

Two things go wrong. First, timing. Botox ordered in January but used across January, February, and March posts its entire cost in January. Revenue trickles in over three months.

January looks unprofitable. February and March look artificially strong. Second, category visibility is gone. All five vendors land in one blended supplies line. You cannot read neurotoxin margin separately from filler margin.

The deeper issue is account type. "Office & Admin Supplies" is an operating expense, not a COGS account. Coding Allergan invoices there pushes the cost below the gross profit line entirely. Injectable revenue shows as nearly 100% gross margin at the top of the P&L. Product cost is buried in operating expenses. The income statement is structurally wrong, not just imprecise.

45-65%
Real injectable gross margin after COGS reconciliation
QuickBooks default coding shows 80%+ apparent gross margin on injectables because product cost is either missing from COGS or timed incorrectly. After reclassifying vendor invoices to dedicated COGS accounts and reconciling against treatment revenue, injectable margin typically runs 45-65% for a well-managed med spa.

How do I enter Allergan invoices in QuickBooks correctly?

Use QuickBooks Products & Services items rather than direct expense line entries. Create a product item for each injectable product, map that item's expense account to a dedicated COGS account, and use the product item every time you enter a vendor bill. QuickBooks routes the cost to the right account from there.

Once it is set up, every Allergan bill for Botox posts to "Injectable COGS - Neurotoxins." Every Galderma bill for Dysport hits the same account. Juvederm and Restylane go to "Injectable COGS - Fillers." Sculptra and Radiesse go to "Injectable COGS - Biostimulators." Your P&L separates injectable costs by category without any manual coding on each bill.

The 6-step QuickBooks fix for injectable COGS

  1. 1
    Create three dedicated COGS accounts in Chart of Accounts. In QuickBooks Online, go to Accounting, then Chart of Accounts. Click New. Set the Account Type to "Cost of Goods Sold." Create three accounts: Injectable COGS, Neurotoxins, Injectable COGS, Fillers, and Injectable COGS, Biostimulators. Do not use a generic Cost of Goods Sold account. Dedicated accounts are what let you pull margin by category.
  2. 2
    Reclassify the past 12 months of vendor invoices. Pull all Allergan, Galderma, Merz, Evolus, and Revance invoices from the past 12 months. Open each bill and change the expense account from the generic supplies account to the correct COGS account. Botox to Neurotoxins. Juvederm and Restylane to Fillers. Sculptra and Radiesse to Biostimulators. This reclassification retroactively fixes 12 months of P&L data.
  3. 3
    Create a Product/Service item for each injectable product. Go to Sales, then Products and Services. Click New, then Service or Non-inventory. Name the item (e.g., "Botox, Allergan"). Check "I purchase this product/service from a vendor." In the Expense account field, select the matching COGS account. Repeat for each product.
  4. 4
    Enter all future vendor invoices using those product items. When an Allergan bill arrives, do not enter it as a direct expense line. Open a new Bill, select Allergan as the vendor, and in the item table use the product items from Step 3. Enter quantity and unit cost. QuickBooks posts to the correct COGS account automatically.
  5. 5
    Run a monthly COGS reconciliation report. At month end, run a Profit and Loss report. Filter to the current month. Divide each Injectable COGS account by its matching injectable service revenue. COGS should run 30 to 40 percent (gross margin 60 to 70 percent). Anything outside that range needs investigation before the month closes.
  6. 6
    Verify margin by service line against your booking system. Pull treatment count and revenue by service type from Zenoti, AestheticsPro, or your POS. Compare total injectable revenue to total injectable COGS in QuickBooks. A COGS spike usually means a large order landed. A drop means treatments ran from existing inventory. A persistent gap with no clear cause means invoices are still miscoded or treatments are going out without a patient charge.

If QuickBooks shows injectable gross margin above 80%, the invoices are almost certainly coded to an operating expense account rather than COGS. The product cost is hidden, not absent.

Common mistake: creating COGS accounts without remapping vendor items

Owners add the three Injectable COGS accounts, check them off the list, and keep entering Allergan bills as direct expense lines to the old Medical Supplies account. The new accounts stay empty. The old account keeps absorbing invoices. Margin on the P&L does not move. The fix only works if every future bill runs through the Products and Services items created in Step 3, and every historical bill from Step 2 has been reclassified. Without both, the structure exists on paper but the numbers stay wrong.

Before and after: what QuickBooks shows on $20,000 of injectable revenue

This calculation uses $20,000 in monthly injectable service revenue with a 35% COGS assumption, consistent with a practice running efficient neurotoxin volume at Allergan wholesale pricing. Left column is what default QuickBooks coding produces. Right column is what the corrected setup shows.

Injectable P&L, $20,000 monthly revenue
Before: default QuickBooks coding
Injectable revenue $20,000
Injectable COGS $0
Gross profit $20,000
Apparent gross margin 100%
Where product cost went Office & Admin Supplies (operating expense)
After: corrected COGS accounts
Injectable revenue $20,000
Injectable COGS $7,000
Gross profit $13,000
Actual gross margin 65%
Where product cost goes Injectable COGS accounts (COGS section)

The $7,000 COGS figure reflects 35% product cost on $20,000 in injectable revenue, using Allergan's approximately $6.56 per unit Botox WAC and blended filler cost assumptions. Your exact figure depends on product mix and vendor pricing tier. The structure is the point: COGS belongs above the gross profit line, in a dedicated account, separated by category.

Important: expensing at purchase vs. at point of care

Expensing product when the invoice arrives and recognizing COGS when the treatment is delivered are two different methods. If you order monthly and use nearly everything that same month, the timing gap is small.

If you carry inventory across months, order in bulk, or keep a standing stock of neurotoxin, the gap is real money. Say you ordered $14,000 of Botox in January but delivered only half the treatments by month end.

January COGS should reflect only what was actually used, not the full $14,000. The rest sits on the balance sheet as inventory until it is used in a treatment. Handling that correctly requires either an inventory asset account in QuickBooks or a monthly journal entry at close. If your bookkeeper is not making that distinction, your P&L margin swings every time you place a large order.

Injectable vendor COGS account mapping

Use this table when setting up product items or reclassifying historical invoices. It covers all five major injectable vendors with the correct QuickBooks account name, account type, and COGS category for each.

Vendor / Product QuickBooks Account Name Account Type COGS Category
Allergan (Botox, Juvederm) Injectable COGS - Neurotoxins
Botox
Injectable COGS - Fillers (Juvederm line)
Cost of Goods Sold Neurotoxins / Fillers
Galderma (Dysport, Restylane) Injectable COGS - Neurotoxins
Dysport
Injectable COGS - Fillers (Restylane line)
Cost of Goods Sold Neurotoxins / Fillers
Merz (Xeomin, Radiesse) Injectable COGS - Neurotoxins
Xeomin
Injectable COGS - Biostimulators (Radiesse)
Cost of Goods Sold Neurotoxins / Biostimulators
Evolus (Jeuveau) Injectable COGS - Neurotoxins Cost of Goods Sold Neurotoxins
Revance (Daxxify) Injectable COGS - Neurotoxins Cost of Goods Sold Neurotoxins

Allergan and Galderma each span two COGS categories because they sell both neurotoxins and fillers. Create separate product items in QuickBooks for each product line, each mapped to its own COGS account. One "Allergan" item pointed at a single account will still blend the categories and defeat the purpose.

What the corrected P&L looks like

With the accounts set up, the injectable section of your monthly P&L reads like this:

  • Injectable Revenue (all neurotoxin and filler service revenue)
  • Injectable COGS - Neurotoxins (Botox, Dysport, Xeomin, Jeuveau, Daxxify invoices)
  • Injectable COGS - Fillers (Juvederm, Restylane, and similar HA filler invoices)
  • Injectable COGS - Biostimulators (Sculptra, Radiesse, and similar invoices)
  • Injectable Gross Profit (revenue minus the three COGS lines above)

Run a Profit and Loss report in QuickBooks, filter to any date range, and your injectable gross margin is right there. You can also compare neurotoxin margin to filler margin to catch which category is underperforming.

Neurotoxin COGS running above 40% of neurotoxin revenue calls for a pricing review or a vendor conversation. Filler margin compressing month over month usually means syringe costs went up or a provider is using more product per treatment than is being billed to the patient.

None of that is visible when injectable costs sit in a single generic supplies account.

We rebuild this chart of accounts as part of every onboarding.

Most practices that come to Spa Ledger show injectable gross margin well above 80% in QuickBooks because product cost is sitting in operating expenses, not COGS. In the first 30 days, we reclassify 12 months of invoices, build out the dedicated COGS account structure, and deliver a clean monthly P&L with margin separated by service line. The first month is on us.

Reserve Your First Month

Frequently asked questions about injectable COGS in QuickBooks

Create a Product/Service item in QuickBooks for each Allergan product (Botox, Juvederm, etc.). Under that item, check "I purchase this product/service from a vendor" and set the expense account to the matching COGS account, such as Injectable COGS - Neurotoxins for Botox. When you enter an Allergan bill, use the product item rather than a generic expense line. QuickBooks posts to the correct COGS account automatically.
Botox purchases should post to a dedicated COGS account named Injectable COGS - Neurotoxins, not to Office Supplies, Medical Supplies, or a generic Cost of Goods Sold account. A separate neurotoxin COGS account lets you calculate gross margin on neurotoxin services independently from filler and biostimulator services.
Injectable COGS as a percentage of injectable service revenue should run 30-40%, which puts gross margin at 60-70%. If QuickBooks shows injectable gross margin above 80%, the invoices are almost certainly coded incorrectly and COGS is understated. Margin below 45% usually means pricing is too low or product waste is not being tracked.
Yes, if your practice orders product before it is used. If Botox or filler arrives and sits in the refrigerator before a treatment, it is a current asset, not an expense. Expensing it at the time of the invoice overstates costs in ordering months and understates them in high-utilization months. The correct treatment is to carry the product as inventory and move it to COGS when it is used in a treatment. Practices that order monthly and use nearly all inventory within that month can use the simpler direct-expense approach, but must still post to a dedicated COGS account rather than a supplies line.
Reclassify at minimum the prior 12 months. That gives you a full year of accurate injectable COGS data for year-over-year comparisons and any tax or financial review. If you are preparing for a sale or bringing on a new investor, reclassify 24-36 months to give buyers a clean historical P&L.
QuickBooks will post invoices to the correct COGS accounts automatically once product items are set up with the right expense account mapping. It will not automatically recognize COGS at the point of treatment if you are using an inventory asset method. For that, a journal entry or a bookkeeper's monthly close process is needed to move product cost from the inventory asset account to the COGS account as treatments are delivered.